Bernstein initiated coverage of Revolution Medicines (RVMD) with a Market Perform rating and $151 price target The firm believes investors should pass on RevMed at this time because the value of future portfolio revenue upside is baked into the current share price. Daraxonrasib, which is on track for its first FDA-label in high-unmet need second-line pancreatic ductal adenocarcinoma with potential launch by the end of 2026, looks like a winner for pancreatic cancer patients and the firm is bullish on the medicine’s potential to extend overall survival, the analyst tells investors in a research note.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
